Maryam I. Azeem

Maryam I. Azeem

Auto-generated profile, based on publicly available information

Maryam I. Azeem

Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2022 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
MAMaryam I. Azeem
Maryam I. Azeem
ANAjay K. Nooka
Ajay K. Nooka
USUma Shanmugasundaram
Uma Shanmugasundaram
NCNarayanaiah Cheedarla
Narayanaiah Cheedarla
SPSayalee Potdar
Sayalee Potdar
KDKavita M. Dhodapkar
Kavita M. Dhodapkar
Patients with multiple myeloma (MM) mount suboptimal neutralizing antibodies (nAb) following 2 doses of SARS-CoV-2 mRNA vaccines. Currently, circulating SARS-CoV-2 variants of concern (VOC) carry the risk of breakthrough infections. We evaluated immune recognition of current VOC including BA.1, BA.2, and BA.5 in 331 racially representative patients with MM following 2 or 3 doses of mRNA vaccines. The third dose increased nAbs against WA1 in 82%, but against BA variants in only 33% to 44% of patients. Vaccine-induced nAbs correlated with receptor-binding domain (RBD)–specific class-switched memory B cells. Vaccine-induced spike-specific T cells were detected in patients without seroconversion and cross-recognized variant-specific peptides but were predominantly CD4+ T cells. Detailed clinical/immunophenotypic analysis identified features correlating with nAb/B/T-cell responses. Patients who developed breakthrough infections following 3 vaccine doses had lower live-virus nAbs, including against VOC. Patients with MM remain susceptible to SARS-CoV-2 variants following 3 vaccine doses and should be prioritized for emerging approaches to elicit variant-nAb and CD8+ T cells. Significance: Three doses of SARS-CoV-2 mRNA vaccines fail to yield detectable VOC nAbs in nearly 60% and spike-specific CD8+ T cells in >80% of myeloma patients. Patients who develop breakthrough infections following vaccination have low levels of live-virus nAb. This article is highlighted in the In This Issue feature, p. 101

24 November 2025
Verified
Other
Open access
MAMaryam I. Azeem
Maryam I. Azeem
ANAjay K. Nooka
Ajay K. Nooka
USUma Shanmugasundaram
Uma Shanmugasundaram
NCNarayanaiah Cheedarla
Narayanaiah Cheedarla
SPSayalee Potdar
Sayalee Potdar
KDKavita M. Dhodapkar
Kavita M. Dhodapkar
Suppl Table 1. Correlative analysis of breakthrough SARS CoV-2 infection following booster vaccination.

4 April 2023
Verified
Other
Open access
MAMaryam I. Azeem
Maryam I. Azeem
ANAjay K. Nooka
Ajay K. Nooka
USUma Shanmugasundaram
Uma Shanmugasundaram
NCNarayanaiah Cheedarla
Narayanaiah Cheedarla
SPSayalee Potdar
Sayalee Potdar
KDKavita M. Dhodapkar
Kavita M. Dhodapkar
Supplementary Table 2: Antibodies used for immune-phenotyping (CyTOF analysis). Supplementary Table 3: Antibodies used for flow cytometry. Supplementary Table 4: Antibodies used for AIM Assay (CyTOF analysis).

4 April 2023
Verified
Other
Open access
MAMaryam I. Azeem
Maryam I. Azeem
ANAjay K. Nooka
Ajay K. Nooka
USUma Shanmugasundaram
Uma Shanmugasundaram
NCNarayanaiah Cheedarla
Narayanaiah Cheedarla
SPSayalee Potdar
Sayalee Potdar
KDKavita M. Dhodapkar
Kavita M. Dhodapkar
Patients with multiple myeloma (MM) mount suboptimal neutralizing antibodies (nAb) following 2 doses of SARS-CoV-2 mRNA vaccines. Currently, circulating SARS-CoV-2 variants of concern (VOC) carry the risk of breakthrough infections. We evaluated immune recognition of current VOC including BA.1, BA.2, and BA.5 in 331 racially representative patients with MM following 2 or 3 doses of mRNA vaccines. The third dose increased nAbs against WA1 in 82%, but against BA variants in only 33% to 44% of patients. Vaccine-induced nAbs correlated with receptor-binding domain (RBD)–specific class-switched memory B cells. Vaccine-induced spike-specific T cells were detected in patients without seroconversion and cross-recognized variant-specific peptides but were predominantly CD4+ T cells. Detailed clinical/immunophenotypic analysis identified features correlating with nAb/B/T-cell responses. Patients who developed breakthrough infections following 3 vaccine doses had lower live-virus nAbs, including against VOC. Patients with MM remain susceptible to SARS-CoV-2 variants following 3 vaccine doses and should be prioritized for emerging approaches to elicit variant-nAb and CD8+ T cells.Significance:Three doses of SARS-CoV-2 mRNA vaccines fail to yield detectable VOC nAbs in nearly 60% and spike-specific CD8+ T cells in >80% of myeloma patients. Patients who develop breakthrough infections following vaccination have low levels of live-virus nAb.This article is highlighted in the In This Issue feature, p. 101

4 April 2023
Verified
Other
Open access
MAMaryam I. Azeem
Maryam I. Azeem
ANAjay K. Nooka
Ajay K. Nooka
USUma Shanmugasundaram
Uma Shanmugasundaram
NCNarayanaiah Cheedarla
Narayanaiah Cheedarla
SPSayalee Potdar
Sayalee Potdar
KDKavita M. Dhodapkar
Kavita M. Dhodapkar
Patients with multiple myeloma (MM) mount suboptimal neutralizing antibodies (nAb) following 2 doses of SARS-CoV-2 mRNA vaccines. Currently, circulating SARS-CoV-2 variants of concern (VOC) carry the risk of breakthrough infections. We evaluated immune recognition of current VOC including BA.1, BA.2, and BA.5 in 331 racially representative patients with MM following 2 or 3 doses of mRNA vaccines. The third dose increased nAbs against WA1 in 82%, but against BA variants in only 33% to 44% of patients. Vaccine-induced nAbs correlated with receptor-binding domain (RBD)–specific class-switched memory B cells. Vaccine-induced spike-specific T cells were detected in patients without seroconversion and cross-recognized variant-specific peptides but were predominantly CD4+ T cells. Detailed clinical/immunophenotypic analysis identified features correlating with nAb/B/T-cell responses. Patients who developed breakthrough infections following 3 vaccine doses had lower live-virus nAbs, including against VOC. Patients with MM remain susceptible to SARS-CoV-2 variants following 3 vaccine doses and should be prioritized for emerging approaches to elicit variant-nAb and CD8+ T cells.Significance:Three doses of SARS-CoV-2 mRNA vaccines fail to yield detectable VOC nAbs in nearly 60% and spike-specific CD8+ T cells in >80% of myeloma patients. Patients who develop breakthrough infections following vaccination have low levels of live-virus nAb.This article is highlighted in the In This Issue feature, p. 101